Drug Trial Radar · NCT05422378
A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty
Last checked: Nov 19, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Aug 1, 2022
Primary completion
Feb 3, 2023
Study completion Jun 27, 2023
Sponsor
- Lead sponsor
- SirnaomicsIndustry
- Sponsor type
- Industry
- First posted
- Jun 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Dose-ranging, randomized, double-blind, vehicle-controlled study
Conditions
- Abdominal Obesity
Interventions
STP705Drug
STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with presence and severity of the following Local Skin Reactions (LSR): erythema, edema, bruising.Time frame: 24 weeks
- Number of subjects with presence and severity of the following Local Skin Reactions (LSR): pain and stinging/burning.Time frame: 24 weeks
- Incidence (severity and causality) of any AEsTime frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Clinical and Cosmetic Research
Aventura, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.